Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Four FDA actions plus five oncology developmental updates from the last week in February

3/5/2019

 
Seven non-oncology development updates included below.

The FDA delayed a decision on NKTR-181 by three months to allow additional time to review preclinical data from two additional studies and set a new PDUFA date of 8/29/2019.

On 2/28/2019, the FDA Oncologic Drugs Advisory Committee recommend a delay in approval of selinexor-dexamethasone to treat triple class-refractory myeloma until after the results of the Phase III BOSTON trial are available in the first half of 2020.

The FDA accepted an NDA for diroximel fumarate on 2/25/2019 suggesting a PDUFA date of 12/25/2019.

The FDA designated AT-GAA as a Breakthrough Therapy in February 2019.

Twelve investigational drug developmental updates: 
  1. Actinium announced interim data from the 47 patients in the 150 patient, Phase III, SIERRA trial, where 92% of patients treated with Iomab-B achieved successful engraftment of allogeneic hematopoietic stem cell transplant prior to day 100 compared to standard of care chemotherapy where 79% of patients failed to achieve a complete response in patients with active, relapsed or refractory acute myeloid leukemia.
  2. Bayer has submitted an NDA for darolutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
  3. In a 59 patient, Phase II, open label trial, treatment with apatinib resulted in a progression-free survival of 3 months and overall survival of 7.93 months in patients with stage IV sarcoma who had failed chemotherapy. 
  4. In a 138 patient, Phase II, open label trial, the addition of PEGPH20 to mFOLFIRINOX increased toxicity and decreased treatment duration compared to mFOLFIRINOX alone in patients with metastatic pancreatic cancer. 
  5. ImmunoGen announced that in a 366 patient, Phase III trial, mirvetuximab soravtansine did not improve progression-free survival compared to standard chemotherapy in patients with platinum-resistant ovarian cancer that expressed medium to high levels of folate receptor alpha and had received up to three prior lines of therapy.
  6. Santhera announced that in the 6-year, open label, SYROS trial, a long-term follow-up in 18 of 64 patients that completed the Phase III DELOS trial, where switching to or maintaining long-term treatment with idebenone reduced the rate of decline in forced vital capacity percent of predicted (FVC%p) by 50% in patients with Duchenne muscular dystrophy.
  7. In a 12-week, 1,208 patient, Phase III, PERFECT 1 trial, more patients treated with trifarotene cream achieved an Investigator Global Assessment of IGA, clear/almost clear and ≥2 grade improvement than placebo (29.4% vs 19.5%), a reduction in facial lesion counts with inflammatory lesions (-19 vs -15.4) and non-inflammatory lesions ( -25 vs -17.9) in patients 9 years or older with moderate facial acne and moderate truncal acne. In a 12-week, 1,212 patient, Phase III, PERFECT 2 trial, more patients treated with trifarotene cream achieved an Investigator Global Assessment of IGA, clear/almost clear and ≥2 grade improvement than placebo (42.3% vs 25.7%), a reduction in facial lesion counts with inflammatory lesions (-24.2 vs -18.7) and non-inflammatory lesions ( -30.1 vs -21.6) in patients 9 years or older with moderate facial acne and moderate truncal acne. Mayne Pharma is evaluating trifarotene in the treatment of Lamellar Ichthyosis in a Phase II trial. Galderma has submitted an NDA for trifarotene for the treatment of facial and truncal acne.
  8. Redhill plans to file an NDA for RHB-105 in the first half of 2019 with a potential launch by the end of the year if the drug is approved. 
  9. Horizon announced that in the 24-week, 83 patient, Phase III, Optic trial, 82.9% of patients treated with teprotumumab had a 2 mm or more reduction in proptosis compared to 9.5% with placebo in patients with active thyroid eye disease. Horizon Pharma plans to file a BLA for teprotumumab in mid-2009. 
  10. CHMP recommended approval of approval of sotagliflozin and risankizumab and conditional marketing authorization for volanesorsen.
  11. In a 12-week, 43 patient, Phase II, open label trial, treatment with NGM282 reduced the NAFLD activity score by 1.9 points with 1 mg and 2.3 points with 3 mg in patients with biopsy‐confirmed nonalcoholic steatohepatitis. The fibrosis score decreased by 0.1 point with 1 mg and 0.5 points with 3 mg.
  12. UCB announced that in a 60-week, long-term follow-up to the Phase IIb BE ABLE trial, 80 to 100% of bimekizumab responders maintained PASI90.

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.